Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|May 19, 2015

International Neonatal Consortium Launched

The Critical Path Institute launched a consortium to help develop therapies for newborns.

 

On May 19, 2015, the Critical Path Institute (C-Path), a non-profit organization, launched the International Neonatal Consortium (INC). INC will bring researchers, drug developers, regulators, and other stakeholders together to collaborate in developing treatments specifically for diseases that effect newborns. The consortium will concentrate on neonatal brain, lung, and gastrointestinal injuries; neonatal sepsis; retinopathy; and neonatal abstinence syndrome.

“Individual organizations simply do not have the data, resources, or expertise to address the many gaps in regulatory science that exist for the neonatal population,” explained C-Path president and CEO Dr. Martha Brumfield, in a press release. “By utilizing our consensus science model and working directly with regulators, we will forge a more efficient regulatory pathway for much-needed neonatal treatments.”

Dr. Alan Bedrick, Chief of Neonatology and Developmental Biology at the University of Arizona College of Medicine–Tucson, will serve as the executive director of the consortium. “The rapidly changing and unique physiology of neonates presents hurdles that often cause one-off approaches to falter,” said Bedrick in the press release. “Only by marshalling forces of the global neonatal community can we address the urgent needs for the care and treatment of neonates.”

Source: Critical Path Institute 


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.